HaleonMEX:HLNN 74 Net Margin % is 15.51% as of Dec. 2025, which is 34% above its 10-year median of 11.58. GuruFocus rates MEX:HLNN with a GF Score™ of 74/100 and a GF Value™ of MXN107.88. The stock has 3 warning signs investors should review. Among 956 Drug Manufacturers companies, Haleon ranks better than 79.39% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Haleon's Net Income for the
six
months ended in Dec. 2025 was MXN20,754 Mil. Haleon's Revenue for the
six
months ended in Dec. 2025 was MXN133,777 Mil. Therefore, Haleon's net margin for the quarter that ended in Dec. 2025 was 15.51%.
The historical rank and industry rank for Haleon's Net Margin % or its related term are showing as below:
MEX:HLNN'
s Net Margin % Range Over the Past 10 Years
Min: 7.72 Med: 11.58 Max: 15.11
Current: 15.11
MEX:HLNN's Net Margin % is ranked better than 79.39% of 956
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs MEX:HLNN: 15.11
Haleon (MEX:HLNN) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Haleon Net Margin % Related Terms
Haleon Net Margin % Historical Data
* Premium members only.
The historical data trend for Haleon's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:HLNN vs ZTS, UTHR, VTRS: Net Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Haleon's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Haleon Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Haleon's Net Margin % distribution charts can be found below:
* The bar in red indicates where Haleon's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Haleon (MEX:HLNN) has a Net Margin % of 15.51% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Haleon and its competitors. This is 34% above median its historical median of 11.58. Over the past decade, Haleon's Net Margin % has ranged from 7.72 to 15.11. According to the industry distribution chart, Haleon ranks #197 out of 956 companies in the Drug Manufacturers industry, placing it in the top 20.6%.
Is Haleon's Net Margin % too high?
Haleon's current Net Margin % of 15.51% is 34% above median its 10-year median of 11.58. Over the past 10 years, this metric has ranged from a low of 7.72 to a high of 15.11. The Drug Manufacturers industry median Net Margin % is 5.56. Haleon's value of 15.51% is 179% above this industry median. Based on the distribution chart, Haleon ranks #197 out of 956 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Haleon has a GF Score™ of 74/100, reflecting its overall financial health beyond just this single metric.
How does Haleon's Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Haleon ranks #197 out of 956 companies for Net Margin %. This places Haleon in the top 21% of its industry — outperforming the majority of peers. The industry median Net Margin % is 5.56. Haleon's value of 15.51% is 179% above this benchmark. Historically, Haleon's own Net Margin % has ranged from 7.72 to 15.11 over the past decade. While the company's 10-year median is 11.58 vs. the industry median of 5.56, Haleon has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Haleon's current Net Margin % of 15.51% is 179% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Haleon and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Haleon's current Net Margin % is 15.51%, which is 34% above median its own 10-year median of 11.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Haleon stock overvalued right now?
Haleon (MEX:HLNN) has a current Net Margin % of 15.51%. The stock's GF Value™ is MXN107.88, compared to a current price of MXN99.17 — trading 8.1% below its estimated fair value. The current Net Margin % is 15.51%, which is 34% above median its 10-year median of 11.58 and 179% above the Drug Manufacturers industry median of 5.56. Haleon's overall GF Score™ is 74/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Haleon (MEX:HLNN), the current Net Margin % is 15.51% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Haleon (MEX:HLNN) Overvalued in 2026?
Based on GuruFocus' analysis, Haleon stock appears to be undervalued.
The current stock price of MXN99.17 is trading 8.1% below its estimated GF Value™ of MXN107.88.
Key valuation signals for MEX:HLNN:
Net Margin %: 15.51% (34% above median its 10-year median of 11.58)
GF Value™: MXN107.88 vs. price of MXN99.17 (8.1% below fair value)
Industry Position: 179% above the Drug Manufacturers median (#197 of 956)
No single metric tells the full story. See the MEX:HLNN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.
74GF Score
Get the complete analysis for MEX:HLNN
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:HLNN has been successfully added to your 
